ডেসিরক্স ডিসপার্সিবল ট্যাবলেট ২৫০ মিগ্রা

ডেসিরক্স ডিসপার্সিবল ট্যাবলেট হল ডিফেরাসিরক্স ২৫০ মিগ্রা সমৃদ্ধ একটি আয়রন চেলেটিং ঔষধ, যা সিপলা লিমিটেড প্রস্তুত করে। ডিসপার্সিবল ট্যাবলেট আকারে প্রাপ্ত এই ঔষধ থ্যালাসেমিয়া, সিকেল সেল ডিজিজ ও মাইলোডিসপ্লাস্টিক সিনড্রোমের কারণে আয়রন ওভারলোডের চিকিৎসায় ব্যবহৃত হয়। মূল্য ৳৫০.০০ প্রতি ট্যাবলেট, ৩০ টির প্যাক ৳১,৫০০.00। ২৫°C এর নিচে শুষ্ক স্থানে সংরক্ষণ করুন।

The drug should be started after the transfusion of approximately 20 units (about 100 ml/kg) of packed red blood cells or evidence of chronic iron overload is present (e.g. serum ferritin >1,000 microgram/L).

The recommended initial daily dose of Deferasirox is 20-40 mg/kg body weight per day in empty stomach preferably half an hour before breakfast. The tablets are dispersed by stirring in a glass of water or apple or orange juice (100 to 200 ml) until a fine suspension is obtained. After the suspension has been swallowed, any residue must be re-suspended in a small volume of water or juice and swallowed, The tablets must not be chewed or swallowed whole. Dispersion in carbonated drinks or milk is not recommended due to foaming and slow dispersion, respectively.

Serum ferritin to be monitored every month and the dose is adjusted accordingly every 3 to 6 months based on the trends in serum ferritin. If iron overload is inadequately controlled, doses of up to 40 mg/kg may be considered. If serum ferritin level is controlled, dose reductions in steps of 5 to 10 mg/kg should be considered to maintain serum ferritin at 500 microgram/l. Dose interruption can be done if sustained control is achieved,

Cytopenias may occur diarrhea, constipation, vomiting, nausea, abdominal pain, abdominal distension, dyspepsia upper gastrointestinal ulceration and hemorrhage have been reported. Headache, dizziness and main
CNS involvement. Elevation of hepatic transaminases may occur. Cases of Stevens-Johnson syndrome (SJS) and skin rash have been rarely reported. Auditory and ocular disturbances may occur.

Pregnancy Category C. There are no adequate and well-controlled studies with Deferasirox in pregnant women. Administration of Deferasirox to animals during pregnancy and lactation resulted in decreased offspring viability and an increase in renal anomalies in male offspring at exposures that were less than the recommended human exposure. Deferasirox should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether Deferasirox is excreted in human milk.

Fatal and non-fatal gastrointestinal bleeding, ulceration, and irritation may occur during Desirox treatment , Use caution in patients who are taking Desirox in combination with drugs that have known ulcerogenic or hemorrhagic potential, such as NSAIDs, corticosteroids, oral bisphosphonates, and anticoagulants.

Cytopenias, including agranulocytosis, neutropenia and thrombocytopenia have been reported. Monitor blood counts during Desirox therapy.

Serious hypersensitivity reactions have been reported, If reactions are severe, discontinue Desirox and institute appropriate medical intervention.

Pediatric use: The safety and efficacy of Desirox in pediatric patients was similar to that of adult patients,
and younger pediatric patients responded similarly to older pediatric patients. The recommended starting dose and dosing modification are the same for children and adults.

Geriatric use: Elderly patients are at increased risk for Desirox toxicity due to the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Renal impairment: Desirox has not been studied in patients with renal impairment.

Hepatic impairment: Desirox has not been studied in patients with hepatic impairment.

The maximal dose of Desirox is 40 mg/kg body weight. There is no information about overdose of Desirox.